Last updated on February 2018

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of INCB050465 when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).

Clinical Study Identifier: NCT03039114

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Banner Health
Gilbert, AZ United States
0.47miles
  Connect »